Comparable stake leader
FMR LLC
SEC ownership of Structure Therapeutics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001888886.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- GPCR on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001888886
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Structure Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
WELLINGTON MANAGEMENT GROUP LLP
10%
Avoro Capital Advisors LLC
9.4%
JANUS HENDERSON GROUP PLC
7.7%
Deep Track Capital, LP
6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
3/4/5
13F
Other*, 10%+ Owner · Company
|
15%
|
$2,163,883,695
31,112,634 shares
|
+$776,609,280 | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
Company
|
10%
|
$1,481,942,431
21,365,952 shares
|
+$50,941,729 | 31 Dec 2025 |
| Avoro Capital Advisors LLC |
13D/G
13F
Company
|
9.4%
|
$454,066,620
16,216,665 shares
|
$0 | 30 Sep 2025 |
| JANUS HENDERSON GROUP PLC |
13F
13D/G
Company
|
7.7%
from 13D/G
|
$258,260,143
5,354,981 shares
|
— | 31 Mar 2026 |
| Deep Track Capital, LP |
13D/G
13F
Company
|
6%
|
$855,579,599
12,335,346 shares
|
-$21,646,354 | 31 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
4.9%
|
$723,914,898
10,437,066 shares
|
+$57,243,848 | 31 Dec 2025 |
| Capital Research Global Investors |
13D/G
|
3.8%
|
$168,218,991
6,492,435 shares
|
$0 | 31 Mar 2025 |
| BVF INC/IL |
13F
Company
|
1.6%
|
$166,741,056
3,459,358 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$5,409,271.
Buys
$0
Insiders: 0
Sells
$5,409,271
Insiders: 2
Net
-$5,409,271
Shares: -103,996
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 103,996
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 25,330 | $0 | $1,347,728 | -$1,347,728 |
| 3-6 | 0 | 17,452 | $0 | $1,453,753 | -$1,453,753 |
| 6-9 | 0 | 34,904 | $0 | $2,137,631 | -$2,137,631 |
| 9-12 | 0 | 26,310 | $0 | $470,160 | -$470,160 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Structure Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Ph.D. Raymond C. Stevens
Net 12M change
-$5,409,271
Latest report
25 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ph.D. Raymond C. Stevens | CHIEF EXECUTIVE OFFICER, Director | $217,700,989 | Mixed | 19 Mar 2026 | ||
| Jun Yoon | Chief Financial Officer | $216,491,068 | Mixed | 19 Mar 2026 | ||
| FMR LLC | Other*, 10%+ Owner | $46,455,733 | -$5,022,625 | -9.8% | Mixed | 14 Apr 2026 |
| Crespo Blas Coll | Chief Medical Officer | $20,585,311 | Mixed | 19 Mar 2026 | ||
| Ramy Farid | Director | $17,176,500 | Mixed | 07 Feb 2023 | ||
| Ashley Hall | Chief Development Officer | $11,361,240 | Mixed | 19 Mar 2026 | ||
| Xichen Lin | Chief Scientific Officer | $11,035,872 | -$386,646 | -3.4% | Mixed | 25 Jun 2026 |
| Yingli Ma | Chief Technology Officer | $10,243,323 | Mixed | 19 Mar 2026 | ||
| Matthew Lang | Coo & Gc | $8,898,394 | Mixed | 15 Apr 2026 | ||
| Mark Allen Bach | Chief Medical Officer | $520,855 | Mixed | 15 Mar 2024 | ||
| Melita Sun Jung | Chief Business Officer | $62,460 | Mixed | 07 Feb 2023 | ||
| Joanne Waldstreicher | Director | Mixed | 17 Jun 2026 | |||
| Sharon Tetlow | Director | Mixed | 17 Jun 2026 | |||
| Eric Dobmeier | Director | Mixed | 17 Jun 2026 | |||
| BVF PARTNERS L P/IL | 10%+ Owner | Mixed | 10 May 2023 | |||
| Daniel G. Welch | Director | Mixed | 17 Jun 2026 | |||
| Angus C. Russell | Director | Mixed | 17 Jun 2026 | |||
| Ted W. Love | Director | Mixed | 17 Jun 2026 | |||
| FIL Ltd | Other* | Mixed | 07 Feb 2023 |
Recent insider transactions for Structure Therapeutics Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Xichen Lin | GPCR | Ordinary Shares | Conversion of derivative security | -9.36% | -23,634 | 228,960 | 25 Jun 2026 | Direct | ||
| Xichen Lin | GPCR | Ordinary Shares | Options Exercise | 10.3% | 23,634 | 252,594 | 25 Jun 2026 | Direct | ||
| Xichen Lin | GPCR | American Depositary Shares | Sale | -100% | $386,646 | $49.08 | -7,878 | 0 | 25 Jun 2026 | Direct |
| Xichen Lin | GPCR | American Depositary Shares | Conversion of derivative security | 7,878 | 7,878 | 25 Jun 2026 | Direct | |||
| Xichen Lin | GPCR | Share Option (right to buy) | Options Exercise | -11% | -23,634 | 190,166 | 25 Jun 2026 | Direct | ||
| Angus C. Russell | GPCR | Share Option (right to buy) | Award | 39,453 | 39,453 | 17 Jun 2026 | Direct | |||
| Ted W. Love | GPCR | Share Option (right to buy) | Award | 39,453 | 39,453 | 17 Jun 2026 | Direct | |||
| Joanne Waldstreicher | GPCR | Share Option (right to buy) | Award | 39,453 | 39,453 | 17 Jun 2026 | Direct | |||
| Eric Dobmeier | GPCR | Share Option (right to buy) | Award | 39,453 | 39,453 | 17 Jun 2026 | Direct | |||
| Sharon Tetlow | GPCR | Share Option (right to buy) | Award | 39,453 | 39,453 | 17 Jun 2026 | Direct | |||
| Daniel G. Welch | GPCR | Share Option (right to buy) | Award | 39,453 | 39,453 | 17 Jun 2026 | Direct | |||
| Matthew Lang | GPCR | Ordinary Shares | Award | 184,614 | 184,614 | 15 Apr 2026 | Direct | |||
| Matthew Lang | GPCR | Share option (right to buy) | Award | 223,776 | 223,776 | 15 Apr 2026 | Direct | |||
| Fmr Llc | GPCR | American Depositary Shares | Sale | -33.3% | $885,801 | $55.07 | -16,085 | 32,171 | 14 Apr 2026 | F-Prime Capital Partners Life Sciences Fund VI LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -33.3% | $75,281 | $55.07 | -1,367 | 2,736 | 14 Apr 2026 | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Ashley Hall | GPCR | Ordinary Shares | Award | 44.4% | 47,706 | 155,187 | 19 Mar 2026 | Direct | ||
| Ashley Hall | GPCR | Employee Stock Option (right to buy) | Award | 59,073 | 59,073 | 19 Mar 2026 | Direct | |||
| Crespo Blas Coll | GPCR | Ordinary Shares | Award | 37% | 75,897 | 280,878 | 19 Mar 2026 | Direct | ||
| Crespo Blas Coll | GPCR | Employee Stock Option (right to buy) | Award | 93,984 | 93,984 | 19 Mar 2026 | Direct | |||
| Yingli Ma | GPCR | Ordinary Shares | Award | 30.3% | 32,526 | 139,917 | 19 Mar 2026 | Direct | ||
| Yingli Ma | GPCR | Employee Stock Option (right to buy) | Award | 40,278 | 40,278 | 19 Mar 2026 | Direct | |||
| Xichen Lin | GPCR | Ordinary Shares | Award | 23.4% | 43,368 | 228,960 | 19 Mar 2026 | Direct | ||
| Xichen Lin | GPCR | Employee Stock Option (right to buy) | Award | 53,703 | 53,703 | 19 Mar 2026 | Direct | |||
| Jun Yoon | GPCR | Ordinary Shares | Award | 8.02% | 104,085 | 1,401,656 | 19 Mar 2026 | Direct | ||
| Jun Yoon | GPCR | Employee Stock Option (right to buy) | Award | 128,892 | 128,892 | 19 Mar 2026 | Direct | |||
| Raymond C. Stevens | GPCR | Ordinary Shares | Award | 22.8% | 260,217 | 1,401,593 | 19 Mar 2026 | Direct | ||
| Raymond C. Stevens | GPCR | Employee Stock Option (right to buy) | Award | 322,230 | 322,230 | 19 Mar 2026 | Direct | |||
| Crespo Blas Coll | GPCR | Ordinary Shares | Tax liability | -5.45% | -11,826 | 204,981 | 03 Mar 2026 | Direct | ||
| Yingli Ma | GPCR | Ordinary Shares | Tax liability | -9.53% | -11,313 | 107,391 | 03 Mar 2026 | Direct | ||
| Xichen Lin | GPCR | Ordinary Shares | Tax liability | -9.17% | -18,735 | 185,592 | 03 Mar 2026 | Direct | ||
| Jun Yoon | GPCR | Ordinary Shares | Tax liability | -1.69% | -22,305 | 1,297,571 | 03 Mar 2026 | Direct | ||
| Ashley Hall | GPCR | Ordinary Shares | Tax liability | -4.31% | -4,836 | 107,481 | 03 Mar 2026 | Direct | ||
| Raymond C. Stevens | GPCR | Ordinary Shares | Tax liability | -4.47% | -53,454 | 1,141,376 | 03 Mar 2026 | Direct | ||
| Fmr Llc | GPCR | American Depositary Shares | Sale | -18% | $890,219 | $83.92 | -10,608 | 48,256 | 15 Jan 2026 | F-Prime Capital Partners Life Sciences Fund VI LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -8.51% | $449,662 | $82.10 | -5,477 | 58,864 | 15 Jan 2026 | F-Prime Capital Partners Life Sciences Fund VI LP LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -25% | $113,872 | $83.30 | -1,367 | 4,103 | 15 Jan 2026 | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -100% | $1,970,192 | $61.24 | -32,170 | 0 | 08 Dec 2025 | F-Prime Capital Partners Life Sciences Fund VI LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -33.3% | -16,085 | 32,170 | 08 Dec 2025 | F-Prime Capital Partners Life Sciences Fund VI LP | ||
| Fmr Llc | GPCR | American Depositary Shares | Sale | -100% | $167,439 | $61.24 | -2,734 | 1 | 08 Dec 2025 | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -33.3% | -1,367 | 2,735 | 08 Dec 2025 | F-Prime Capital Partners Life Sciences Advisors Fund VI LP | ||
| Ashley Hall | GPCR | American Depositary Shares | Award | 105.3% | 237 | 462 | 20 Nov 2025 | Direct | ||
| Raymond C. Stevens | GPCR | American Depositary Shares | Award | 82.4% | 824 | 1,824 | 20 Nov 2025 | Direct | ||
| Ashley Hall | GPCR | Ordinary Shares | Tax liability | -5.09% | -6,021 | 112,317 | 18 Sep 2025 | Direct | ||
| Crespo Blas Coll | GPCR | Ordinary Shares | Tax liability | -3.6% | -8,106 | 216,807 | 18 Sep 2025 | Direct | ||
| Fmr Llc | GPCR | American Depositary Shares | Sale | -1.71% | $470,160 | $17.87 | -26,310 | 1,515,558 | 30 Jul 2025 | Shares held by persons and entities whose shares are subject to reporting by the undersigned |
* marks a reported price that did not pass the local price check.